Thompson M D, Gallagher W J, Iaizzo P A, Lanier W L
Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Anesthesiology. 2000 Nov;93(5):1279-84. doi: 10.1097/00000542-200011000-00022.
In the rat model of forebrain ischemia, long-term dexamethasone treatment is reported to cause hyperglycemia and worsen postischemic functional and histologic injury. This effect was assumed to result from glucose enhancement of intraischemic lactic acidosis within the brain. Short-term insulin therapy restored normoglycemia but did not return histologic injury completely to baseline values. Using a nonischemic rat model, the current study attempted to identify a metabolic basis for such outcome data.
Fifty-eight halothane-anesthetized (1.3% inspired) Sprague-Dawley rats were assigned randomly to be administered either no treatment (N = 18) or 2 mg/kg intraperitoneal dexamethasone (N = 40). The latter were administered dexamethasone 3 h before the study only (N = 8) or for 3 h before the study plus daily for 1 day (N = 8), 2 days (N = 8), or 4 days (N = 16). Of the rats treated with dexamethasone for 4 days, one half (N = 8) were administered an insulin-containing saline infusion subsequently to restore normoglycemia short-term. All other rats (N = 50) were administered an infusion of saline without insulin. Plasma glucose was quantified, and brains were excised after in situ freezing. Brain glucose and glycogen concentrations were measured using enzymatic fluorometric analyses.
After 4 days of dexamethasone treatment, plasma glucose was 159% greater than in rats administered placebo (i.e., 22.01 +/- 4.66 vs. 8.51 +/- 1.65 micromol/ml; mean +/- SD; P < 0.0001). Brain glucose concentrations increased parallel to plasma glucose. An insulin infusion for 27 +/- 5 min restored normoglycemia but resulted in a brain-to-plasma glucose ratio that was 32% greater than baseline values (P < 0.01). Neither dexamethasone nor the combination of dexamethasone plus insulin affected brain glycogen concentrations.
In a nonischemic rat model, dexamethasone alone had no independent effect on the brain-to-plasma glucose ratio. However, short-term insulin therapy caused a dysequilibrium between plasma and brain glucose, resulting in an underestimation of brain glucose concentrations when normoglycemia was restored. The dysequilibrium likely was caused by the rapid rate of glucose reduction. The magnitude of the effect may account for the failure of insulin to reverse dexamethasone enhancement of neurologic injury completely in a previous report that used the rat model of forebrain ischemia.
在大鼠前脑缺血模型中,据报道长期使用地塞米松治疗会导致高血糖,并加重缺血后功能和组织学损伤。这种效应被认为是由于脑内缺血性乳酸酸中毒时葡萄糖增加所致。短期胰岛素治疗可恢复血糖正常,但并未使组织学损伤完全恢复至基线值。本研究使用非缺血大鼠模型,试图确定这些结果数据的代谢基础。
58只接受氟烷麻醉(吸入浓度1.3%)的Sprague-Dawley大鼠被随机分为两组,一组不接受治疗(n = 18),另一组腹腔注射2 mg/kg地塞米松(n = 40)。后者仅在研究前3小时给予地塞米松(n = 8),或在研究前3小时给予地塞米松并每日持续1天(n = 8)、2天(n = 8)或4天(n = 16)。在接受地塞米松治疗4天的大鼠中,一半(n = 8)随后接受含胰岛素的生理盐水输注以短期恢复血糖正常。所有其他大鼠(n = 50)接受不含胰岛素的生理盐水输注。测定血浆葡萄糖水平,原位冷冻后切除大脑。采用酶荧光分析法测量脑葡萄糖和糖原浓度。
地塞米松治疗4天后,血浆葡萄糖水平比给予安慰剂的大鼠高159%(即22.01±4.66对8.51±1.65 μmol/ml;均值±标准差;P < 0.0001)。脑葡萄糖浓度与血浆葡萄糖平行升高。输注胰岛素27±5分钟可恢复血糖正常,但导致脑与血浆葡萄糖比值比基线值高32%(P < 0.01)。地塞米松单独使用或地塞米松与胰岛素联合使用均不影响脑糖原浓度。
在非缺血大鼠模型中,单独使用地塞米松对脑与血浆葡萄糖比值无独立影响。然而,短期胰岛素治疗导致血浆和脑葡萄糖之间失衡,导致恢复血糖正常时脑葡萄糖浓度被低估。这种失衡可能是由葡萄糖快速降低所致。这种效应的程度可能解释了在先前使用大鼠前脑缺血模型的报告中胰岛素未能完全逆转地塞米松对神经损伤的增强作用。